News
CLDX
43.86
+11.57%
4.55
Celldex Stock Fairly Valued Amid Competition and Market Anticipation: Hold Rating Maintained
TipRanks · 3d ago
Weekly Report: what happened at CLDX last week (0715-0719)?
Weekly Report · 4d ago
Analyst Expectations For Celldex Therapeutics's Future
Celldex Therapeutics (NASDAQ:CLDX) is a biopharmaceutical company. The company is focused on the development and commercialization of cancer-targeting biologics. In the last three months, 5 analysts have released ratings for CelldexTherapeutics. The average price target for the company is $77.4. The firm has a 12-month average target of $80.00.
Benzinga · 07/16 19:01
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Dow Jones · 07/16 17:42
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Benzinga · 07/16 17:31
Buy Rating Affirmed for Celldex as Barzolvolimab Shows Promise in CSU Treatment Trials
TipRanks · 07/16 13:35
CELLDEX THERAPEUTICS INC -EMBARQ-CSU1 AND EMBARQ-CSU 2 WILL ENROLL MORE THAN 1800 PATIENTS SUFFERING FROM CSU
Reuters · 07/16 12:01
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Barchart · 07/16 07:01
Weekly Report: what happened at CLDX last week (0708-0712)?
Weekly Report · 07/15 11:04
Weekly Report: what happened at CLDX last week (0701-0705)?
Weekly Report · 07/08 11:06
Weekly Report: what happened at CLDX last week (0624-0628)?
Weekly Report · 07/01 11:06
Weekly Report: what happened at CLDX last week (0617-0621)?
Weekly Report · 06/24 11:13
Stifel starts Celldex at buy, sees lead drug as potential blockbuster
Healthcare Stifel starts Celldex at buy, sees lead drug as potential blockbuster. The investment bank believes the drug barzolvolimab could achieve peak US sales of $2.8B. The drug is being developed for the treatment of chronic spontaneous urticaria.
Seeking Alpha · 06/18 17:18
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Aerovate Therapeutics, Boeing and Wingstop are among the companies. Boeing cuts its target price to $210 from $215. Aaron's Company, Abbvie and Chipotle Mexican Grill among those with positive reports.
Reuters · 06/18 15:29
Celldex Therapeutics Price Target Maintained With a $67.00/Share by Cantor Fitzgerald
Dow Jones · 06/18 13:54
Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Benzinga · 06/18 13:45
CELLDEX THERAPEUTICS INC <CLDX.O>: STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $58
Reuters · 06/18 11:00
Stocks Post Modest Gains on Mixed US Economic Reports
US May manufacturing production rose +0.9% m/m, stronger than expected. Weaker-than-expected US May retail sales report eases consumer spending concerns. The S&P 500 Index is up 0.17% today. A decline in T-note yields today is supporting modest gains in stocks. European stock markets are higher.
Barchart · 06/18 09:06
Celldex Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 06/17 23:36
Buy Rating on Celldex’s Barzolvolimab: A Potential Best-in-Class Biologic for Chronic Spontaneous Urticaria
TipRanks · 06/17 20:26
More
Webull provides a variety of real-time CLDX stock news. You can receive the latest news about Celldex Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.